BRPI0911678A2 - forma cristalina anidrosa de maleato de orvepitant - Google Patents

forma cristalina anidrosa de maleato de orvepitant

Info

Publication number
BRPI0911678A2
BRPI0911678A2 BRPI0911678A BRPI0911678A BRPI0911678A2 BR PI0911678 A2 BRPI0911678 A2 BR PI0911678A2 BR PI0911678 A BRPI0911678 A BR PI0911678A BR PI0911678 A BRPI0911678 A BR PI0911678A BR PI0911678 A2 BRPI0911678 A2 BR PI0911678A2
Authority
BR
Brazil
Prior art keywords
crystalline form
anhydrous crystalline
orvepitant maleate
orvepitant
maleate
Prior art date
Application number
BRPI0911678A
Other languages
English (en)
Inventor
Franco Sartor
Ian Philip Steeples
Stefania Beato
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0911678A2 publication Critical patent/BRPI0911678A2/pt
Publication of BRPI0911678B1 publication Critical patent/BRPI0911678B1/pt
Publication of BRPI0911678B8 publication Critical patent/BRPI0911678B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cephalosporin Compounds (AREA)
BRPI0911678A 2008-04-11 2009-04-09 maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central BRPI0911678B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0806652.4 2008-04-11
GBGB0806652.4A GB0806652D0 (en) 2008-04-11 2008-04-11 Anhydrous crystal form of orvepitant maleate
PCT/EP2009/054295 WO2009124996A1 (en) 2008-04-11 2009-04-09 Anhydrous crystal form of orvepitant maleate

Publications (3)

Publication Number Publication Date
BRPI0911678A2 true BRPI0911678A2 (pt) 2015-10-13
BRPI0911678B1 BRPI0911678B1 (pt) 2021-03-02
BRPI0911678B8 BRPI0911678B8 (pt) 2021-05-25

Family

ID=39433527

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911678A BRPI0911678B8 (pt) 2008-04-11 2009-04-09 maleato de orvepitant cristalino anidro, composição farmacêutica compreedendo o dito maleato e uso do mesmo para o tratamento ou profilaxia de doenças do sistema nervoso central

Country Status (27)

Country Link
US (1) US8309553B2 (pt)
EP (1) EP2297152B1 (pt)
JP (2) JP5875863B2 (pt)
KR (1) KR20110002090A (pt)
CN (1) CN102066376B (pt)
AR (1) AR071311A1 (pt)
AU (1) AU2009235440B2 (pt)
BR (1) BRPI0911678B8 (pt)
CA (1) CA2721119C (pt)
CL (1) CL2009000876A1 (pt)
CY (1) CY1115961T1 (pt)
DK (1) DK2297152T3 (pt)
EA (1) EA017082B1 (pt)
ES (1) ES2529295T3 (pt)
GB (1) GB0806652D0 (pt)
HR (1) HRP20141196T1 (pt)
IL (1) IL208597A0 (pt)
MX (1) MX2010011152A (pt)
PE (1) PE20091839A1 (pt)
PL (1) PL2297152T3 (pt)
PT (1) PT2297152E (pt)
RS (1) RS53732B1 (pt)
SI (1) SI2297152T1 (pt)
TW (1) TW201002714A (pt)
UY (1) UY31758A (pt)
WO (1) WO2009124996A1 (pt)
ZA (1) ZA201007120B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8139718B2 (en) * 2007-10-30 2012-03-20 Elekta Ab (Publ) Radiotherapy apparatus
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
MX362879B (es) * 2012-10-11 2019-02-21 Nerre Therapeutics Ltd Usos novedosos.
EP3377064B1 (en) * 2016-01-08 2019-06-26 NeRRe Therapeutics Limited Orvepitant for the treatment of chronic cough
CN110730662A (zh) 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法
US11266633B2 (en) 2017-06-30 2022-03-08 Chase Therapeutics Corporation NK-1 antagonist compositions and methods for use in treating depression
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
CA3173697A1 (en) 2020-04-03 2021-10-07 Mike TROWER An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
BR112022024208A2 (pt) 2020-06-02 2022-12-20 Nerre Therapeutics Ltd Antagonistas do receptor de neurocinina (nk)-1 para uso no tratamento de condições de fibrose pulmonar promovidas por lesão mecânica aos pulmões

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
KR20090024140A (ko) 2006-05-22 2009-03-06 반다 파마슈티칼즈, 인코퍼레이티드. 우울증 질환에 대한 치료
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
WO2009059326A2 (en) * 2007-11-02 2009-05-07 Entegris, Inc. Integral face seal
GB0806652D0 (en) * 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate

Also Published As

Publication number Publication date
US8309553B2 (en) 2012-11-13
EP2297152A1 (en) 2011-03-23
CN102066376B (zh) 2014-01-01
EP2297152B1 (en) 2014-11-12
JP5875863B2 (ja) 2016-03-02
BRPI0911678B8 (pt) 2021-05-25
ES2529295T3 (es) 2015-02-18
PL2297152T3 (pl) 2015-04-30
EA201071183A1 (ru) 2011-06-30
PE20091839A1 (es) 2010-01-07
IL208597A0 (en) 2010-12-30
WO2009124996A1 (en) 2009-10-15
DK2297152T3 (da) 2015-01-26
GB0806652D0 (en) 2008-05-14
UY31758A (es) 2009-11-10
CY1115961T1 (el) 2017-01-25
MX2010011152A (es) 2010-12-21
AU2009235440A1 (en) 2009-10-15
AR071311A1 (es) 2010-06-09
JP2014205688A (ja) 2014-10-30
KR20110002090A (ko) 2011-01-06
BRPI0911678B1 (pt) 2021-03-02
RS53732B1 (en) 2015-06-30
TW201002714A (en) 2010-01-16
ZA201007120B (en) 2011-11-30
HRP20141196T1 (hr) 2015-02-13
CN102066376A (zh) 2011-05-18
JP2011516532A (ja) 2011-05-26
AU2009235440B2 (en) 2012-06-14
SI2297152T1 (sl) 2015-02-27
PT2297152E (pt) 2015-02-16
CA2721119C (en) 2016-04-05
US20110166150A1 (en) 2011-07-07
CA2721119A1 (en) 2009-10-15
EA017082B1 (ru) 2012-09-28
CL2009000876A1 (es) 2010-05-14

Similar Documents

Publication Publication Date Title
LTPA2018008I1 (lt) Kristalai
BRPI0915714A2 (pt) forma cristalina de posaconazol
DK2262793T3 (da) Krystallinske former af nilotinib-hci
BRPI0911678A2 (pt) forma cristalina anidrosa de maleato de orvepitant
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
GB0819182D0 (en) Crystalline forms
BR112012006638A2 (pt) hidratos de cloreto de metiltionínio cristalinos
BRPI1013493A2 (pt) composto de pirimidina
FI20086008A0 (fi) Muodostusosa
SMT201600031B (it) Composti eterociclici di fenossimetile
IT1393443B1 (it) Stiratoio bitesta
HK1164698A1 (en) Crystalline forms of genistein
SMT201700085B (it) Forma cristallina di pemirolast
SI2303866T1 (sl) Kristalne oblike natrijevega rabeprazolata
BR112012009784A2 (pt) composto benzazepínico
BR112012003059A2 (pt) inibidores de jnk
GB0710680D0 (en) Novel crystalline form of olmesartan medoxmil
IT1395981B1 (it) Granitore
DK2280691T3 (da) Krystallinsk DOPC
FI20095440A (fi) Muodostusosa
FI20086007A0 (fi) Muodostusosa
HUP0800755A2 (en) Crystalline forms of rosiglitazone
BRPI1014080A2 (pt) Compostos substituidos de enaminocarbolina
ITRA20080006A1 (it) Facciata continua
TH105747B (th) รูปแบบผลึกของไนโตรเคทิคอล

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: GLAXO GROUP LIMITED (GB)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 20130082868 DE 15/10/2013, E NECESSARIO APRESENTAR O DOCUMENTO COM A DEVIDA LEGALIZACAO CONSULAR.

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: GLAXO GROUP LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: NERRE THERAPEUTICS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF